Literature DB >> 2361822

Acute epidemic aluminium osteomalacia secondary to water supply contamination.

A A O'Brien1, D P Moore, J A Keogh.   

Abstract

When the aluminium content of the water supply to our Haemodialysis Unit rose from less than 0.5 mumol/l to 6 mumol/l over a two month period, we carried out bone biopsies and desferrioxamine infusion tests on twelve (12) patients who had been on haemodialysis for less than one year (mean 8 months) and had normal serum aluminium levels. The patients had no bone symptoms. Eight patients had positive aluminium bone stains. The aluminium osteomalacia group (n = 8) had a mean PTH of 1.4 ng/ml s.e. 0.3 whereas the non-ALO group had a mean PTH of 2.9 ng/ml s.e. 0.7. The difference in mean PTH is significant (p less than 0.05). There was no evidence of encephalopathy, fractures or microcytic anaemia in the ALO positive group. The aluminium contamination of the water supply occurred because of a change in the reservoir purification system from sand-filtration to alum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2361822     DOI: 10.1007/bf02946671

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

1.  Hyperaluminaemia from aluminum resins in renal failure.

Authors:  G M Berlyne; J Ben-Ari; D Pest; J Weinberger; M Stern; R Levine; G R Gilmore
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

2.  Haemodialysis related osteomalacia: a staining method to demonstrate aluminium.

Authors:  M R Buchanan; B U Ihle; C M Dunn
Journal:  J Clin Pathol       Date:  1981-12       Impact factor: 3.411

3.  Aluminium hydroxide intake: real risk of aluminium toxicity.

Authors:  J B Cannata; J D Briggs; B J Junor; G S Fell
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

4.  Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome.

Authors:  K C Norris; P W Crooks; H G Nebeker; G Hercz; D S Milliner; K Gerszi; E Slatopolsky; D L Andress; D J Sherrard; J W Coburn
Journal:  Am J Kidney Dis       Date:  1985-11       Impact factor: 8.860

5.  Treatment of fracturing renal osteodystrophy by desferrioxamine.

Authors:  P Ackrill; J P Day; F M Garstang; K C Hodge; P J Metcalfe; Z Benzo; K Hill; A J Ralston; J Ball; J Denton
Journal:  Proc Eur Dial Transplant Assoc       Date:  1983

6.  Osteomalacia in patients with chronic renal failure before dialysis or transplantation.

Authors:  F J Mora Palma; H A Ellis; D B Cook; J H Dewar; M K Ward; R Wilkinson; D N Kerr
Journal:  Q J Med       Date:  1983

7.  Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance in iliac bone.

Authors:  H H Malluche; W Meyer; D Sherman; S G Massry
Journal:  Calcif Tissue Int       Date:  1982-09       Impact factor: 4.333

8.  Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey.

Authors:  I S Parkinson; M K Ward; T G Feest; R W Fawcett; D N Kerr
Journal:  Lancet       Date:  1979-02-24       Impact factor: 79.321

9.  The efficacy of various treatment modalities on aluminium associated bone disease.

Authors:  B U Ihle; M R Buchanan; B Stevens; G J Becker; P Kincaid-Smith
Journal:  Proc Eur Dial Transplant Assoc       Date:  1983

10.  Suppression of parathyroid hormone secretion by aluminum.

Authors:  J Morrissey; M Rothstein; G Mayor; E Slatopolsky
Journal:  Kidney Int       Date:  1983-05       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.